STAC-9

Last updated
STAC-9
STAC-9 structure.png
Identifiers
  • N-pyridin-4-yl-6-[3-(trifluoromethyl)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine-1-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H15F3N4O
Molar mass 384.362 g·mol−1
3D model (JSmol)
  • C1CN(C2=C1C=CC(=N2)C3=CC(=CC=C3)C(F)(F)F)C(=O)NC4=CC=NC=C4
  • InChI=1S/C20H15F3N4O/c21-20(22,23)15-3-1-2-14(12-15)17-5-4-13-8-11-27(18(13)26-17)19(28)25-16-6-9-24-10-7-16/h1-7,9-10,12H,8,11H2,(H,24,25,28)
  • Key:WFPOEJCACZIDSN-UHFFFAOYSA-N

STAC-9 is an experimental drug that was developed by GlaxoSmithKline as a small-molecule activator of the sirtuin subtype SIRT1, with potential applications in the treatment of diabetes. [1] [2] [3]

See also

References

  1. ↑ US 9556201,Ng PY, Blum C, Mcpherson L, Perni RB, Vu CB, Ahmed MM, Disch JS,"Bicyclic pyridines and analogs as sirtuin modulators.",published 4 October 2012, assigned to Sitris Pharmaceuticalsand GlaxoSmithKline
  2. ↑ Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, et al. (March 2013). "Evidence for a common mechanism of SIRT1 regulation by allosteric activators". Science. 339 (6124): 1216–9. Bibcode:2013Sci...339.1216H. doi:10.1126/science.1231097. PMC   3799917 . PMID   23471411.
  3. ↑ Thevis M, Schänzer W (March 2016). "Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis - Potential implications for sports drug testing programs". Rapid Communications in Mass Spectrometry. 30 (5): 635–51. Bibcode:2016RCMS...30..635T. doi:10.1002/rcm.7470. PMID   26842585. S2CID   206444739.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.